Diagnostics

Annexon Biosciences spotlights its novel C1q inhibitor, Vonaprument, aiming to be the first therapy to preserve vision in geographic atrophy patients.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

Israeli tech firm Nanox will debut its low-cost Nanox.ARC imaging system in Europe, pairing it with AI that spots chronic disease in routine scans.

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.

A new program in Michigan uses AI to analyze existing CT scans, detecting silent heart risks and connecting patients to care before symptoms even appear.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

A new health tech company has assembled a star-studded scientific board to back its AI-powered dementia prevention app. But can it deliver on its promise?

A second real-world study finds an FDA-approved device brings significant relief to over 80% of tinnitus patients, offering new hope for millions.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

LEX Diagnostics' newly FDA-cleared VELO system delivers lab-quality PCR results for flu & COVID in under 10 minutes, set to revolutionize point-of-care testing.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

Researchers have developed a robust, wearable sensor that detects dangerous ammonia gas through both color and electronics, promising a new era of smart PPE.

Blue Cross and MassChallenge award five startups $50k each to solve critical health disparities, from endometriosis diagnosis to language access in hospitals.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.

A new integrated test from NeoGenomics aims to slash diagnostic delays and streamline complex tumor profiling, promising faster, smarter cancer treatment.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?